Brought to you by 
Celgene Options Four Immunotherapy Candidates from Dragonfly; Deal Expanded to Eight Targets; BMS Exercises Five I-O Options so Far
06 Jan 2023
Executive Summary
Celgene Corp. paid $33mm up front for an exclusive option to license global rights to up to four of Dragonfly Therapeutics Inc.’s immuno-oncology projects.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene Options Four Immunotherapy Candidates from Dragonfly; Deal Expanded to Eight Targets; BMS Exercises Five I-O Options so Far
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice